Stock listing

NASDAQ:CTXR Citius Pharmaceuticals, Inc. Stock

Home listing (NASDAQ) of Citius Pharmaceuticals, Inc.

Follow Citius Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:CTXR

$0.509 USD -0.002 (-0.4%)

Close on Nov 20, 2026

Past year -48.6% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.481 – $0.514 USDNov 20, 2026
Volume
183,702 sharesNov 20, 2026
Market cap
$13.96M USDAt the close on Nov 20, 2026 · price × 27.45M shares outstanding
52-week range
$0.370 – $1.540 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$151,992 USDMedian day 209,300 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Citius Pharmaceuticals, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:CTXR · Home$0.509 USD-0.002 (-0.4%)183,702$0.481$0.514$0.481$0.511Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CTXR · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.509-0.002-0.4%$0.481$0.514$0.481183,702
$0.511-0.008-1.6%$0.530$0.530$0.50065,395
$0.519-0.009-1.7%$0.512$0.539$0.503117,023
$0.528-0.008-1.4%$0.545$0.545$0.500150,672
$0.535+0.003+0.5%$0.540$0.544$0.496173,130
$0.532+0.052+10.8%$0.475$0.571$0.461650,807
$0.481-0.012-2.5%$0.491$0.500$0.481176,573
$0.493-0.033-6.4%$0.529$0.545$0.476302,133
$0.526-0.019-3.4%$0.538$0.572$0.510265,436
$0.545-0.012-2.2%$0.590$0.595$0.531199,456
$0.557+0.006+1.2%$0.564$0.597$0.520366,318
$0.551-0.022-3.9%$0.562$0.571$0.542138,079
$0.573+0.011+2.0%$0.560$0.573$0.52098,272
$0.562+0.039+7.4%$0.528$0.570$0.520372,737
$0.523-0.040-7.1%$0.564$0.564$0.52199,493
$0.563+0.022+4.1%$0.525$0.610$0.484402,870
$0.541+0.040+7.9%$0.500$0.550$0.480201,084
$0.502+0.052+11.6%$0.442$0.525$0.408521,722
$0.449+0.046+11.5%$0.404$0.470$0.395370,063
$0.403+0.032+8.6%$0.377$0.410$0.370435,300
$0.371-0.025-6.3%$0.390$0.391$0.370340,000
$0.396-0.022-5.3%$0.410$0.413$0.394383,600
$0.418-0.010-2.3%$0.434$0.436$0.418187,900
$0.428-0.032-7.0%$0.460$0.469$0.414526,900
$0.4600.0000.0%$0.460$0.475$0.460141,000
$0.460-0.005-1.1%$0.460$0.487$0.460303,100
$0.465-0.011-2.3%$0.462$0.470$0.450233,600
$0.476-0.017-3.4%$0.481$0.500$0.460192,800
$0.493-0.006-1.2%$0.490$0.510$0.480119,700
$0.499+0.010+2.0%$0.490$0.510$0.480144,200
$0.489-0.012-2.4%$0.490$0.521$0.480132,400
$0.501+0.020+4.2%$0.489$0.510$0.488161,700
$0.481-0.039-7.5%$0.520$0.526$0.480419,100
$0.520-0.012-2.3%$0.522$0.540$0.520132,600
$0.532-0.008-1.5%$0.533$0.549$0.52580,500
$0.540+0.009+1.7%$0.546$0.568$0.530154,800
$0.531-0.024-4.3%$0.560$0.569$0.530127,400
$0.555+0.006+1.1%$0.550$0.560$0.550150,300
$0.549-0.030-5.2%$0.570$0.590$0.526279,500
$0.579+0.009+1.6%$0.570$0.596$0.56765,200
$0.570+0.001+0.2%$0.570$0.585$0.560154,400
$0.569-0.029-4.8%$0.604$0.610$0.569223,100
$0.598+0.021+3.6%$0.570$0.607$0.570214,900
$0.577-0.023-3.8%$0.587$0.602$0.572155,300
$0.600+0.012+2.0%$0.600$0.604$0.583280,300
$0.588+0.028+5.0%$0.571$0.600$0.571245,000
$0.5600.0000.0%$0.560$0.575$0.560139,300
$0.560-0.013-2.3%$0.580$0.585$0.560129,000
$0.573-0.008-1.4%$0.580$0.590$0.570209,300
$0.581-0.004-0.7%$0.586$0.595$0.581153,800
$0.585+0.003+0.5%$0.600$0.610$0.581165,000
$0.582-0.019-3.2%$0.601$0.610$0.58176,500
$0.601+0.013+2.2%$0.581$0.617$0.580310,500
$0.588-0.014-2.3%$0.602$0.610$0.580299,600
$0.602+0.022+3.8%$0.585$0.614$0.585250,600
$0.580+0.011+1.9%$0.563$0.590$0.563222,100
$0.569-0.011-1.9%$0.580$0.590$0.569226,200
$0.580-0.022-3.7%$0.580$0.593$0.570280,900
$0.602-0.027-4.3%$0.619$0.630$0.590361,600
$0.629+0.052+9.0%$0.577$0.650$0.577824,800
$0.577-0.027-4.5%$0.596$0.610$0.570442,500
$0.604+0.029+5.0%$0.578$0.670$0.5782,160,400
$0.575-0.025-4.2%$0.610$0.610$0.570392,900
$0.6000.0000.0%$0.605$0.613$0.600159,400
$0.600-0.038-6.0%$0.637$0.643$0.571588,500

Splits

2 splits since 2017 · NASDAQ:CTXR · every price before a split is adjusted for it

DayRatioWhat
1-for-25Consolidation
1-for-15Consolidation
Ticker
NASDAQ:CTXR
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Citius Pharmaceuticals, Inc. news

Citius Pharmaceuticals, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
29 in the last 12 months · 152 in all · newest Nov 11, 2026 · oldest 2019
Decks
27 decks · latest Dec 1, 2025

Where Citius Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:CTXR · Home listing · This pageNASDAQUnited StatesUSD
BOATS:CTXRBOATSUnited StatesUSD
gettex:47N0gettexGermanyEUR
Lang & Schwarz:A40MD0Lang & SchwarzGermanyEUR
Frankfurt:47N0FrankfurtGermanyEUR
Munich:47N0MunichGermanyEUR

Valuation

Price/book 0.2× against a median of 0.9×: the lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
−$3.05M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
0.2×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.71

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Citius Pharmaceuticals, Inc. · NASDAQ:CTXRUS$13.96M−US$3.05Mn/an/an/a0.2×n/a0.0×1.71
Hepion Pharmaceuticals, Inc. · OTC:HEPAUS$14.63MUS$10.37Mn/an/an/an/an/an/a-1.02
Vectorite Biomedical, Inc. · TPEX:4170US$14.21MUS$9.16M4.9×4.9×n/a0.9×156.6%0.0×n/a
Estrella Immunopharma, Inc. · NASDAQ:ESLAUS$14.11MUS$14.01Mn/an/an/an/an/an/a1.31
TaiwanJ Pharmaceuticals Co., Ltd. · TPEX:6549US$13.69MUS$11.86Mn/an/an/a7.0×n/a0.0×n/a
Actuate Therapeutics, Inc. · NASDAQ:ACTUUS$13.60MUS$11.50Mn/an/an/an/an/an/a1.75
BeyondSpring, Inc. · NASDAQ:BYSIUS$13.57MUS$12.99M0.3×n/an/a0.9×n/a0.0×1.31
Acumen Pharmaceuticals, Inc. · NASDAQ:ABOSUS$13.49M−US$38.84Mn/an/an/a0.4×n/a0.8×1.45
Pharma Equity Group A/S Class A · OMXCOP:PEGUS$13.47MUS$15.05Mn/an/a52.7×3.6×n/a0.4×n/a
BioInvent International AB · OMXSTO:BINVUS$13.45M−US$6.62Mn/a−1.7×n/a0.7×n/a0.1×n/a
Thalia Therapeutics PLC · LSE:THATUS$13.36MUS$11.39Mn/a1,199×n/a4.2×n/a0.0×n/a
Median of the othersUS$13.59MUS$11.45M2.6×4.9×52.7×0.9×156.6%0.0×1.31

Forecasts

1 strong buy · Analysts' consensus from EODHD, read Nov 16, 2026. Not 6ix's view and not investment advice.

Price target
4.00 USD · Analysts' mean
EPS, year to Sep 2026
-2.03 · 1 analyst
Revenue, year to Sep 2026
10.05M · 1 analyst

Team and board

Officers

OfficerRole
Leonard MazurCo-Founder, CEO and Chairman of the Board of Directors
Jaime BartushakChief Financial Officer & Chief Business Officer
Alan LaderSVP, Head of Clinical Operations and Quality Assurance
Catherine KesslerEVP, Regulatory Affairs
Gary F. TalaricoEVP, Operations
Jay WadekarSVP, Business Strategy
Kelly CreightonEVP, Chemistry, Manufacturing and Controls
Kevin CareyVP, Program & Alliance Management
Michael McGuireVP, Commercial
Myron S. CzuczmanChief Medical Officer and EVP
Nikolas BurlewEVP, Quality Assurance
Myron HolubiakCo-Founder, Executive Vice Chairman

Board

DirectorRole
Leonard MazurCo-Founder, CEO and Chairman of the Board of Directors
Carol WebbDirector
Dennis M. McGrathDirector
Eugene HolukaDirector
Myron HolubiakCo-Founder, Executive Vice Chairman
Robert SmithDirector
Suren DutiaDirector

Events

Next results
Dec 22, 2026 (expected)
QuarterResultsShare move
Q3 2026Aug 14, 2026 · After close−25.7%
Q2 2026May 15, 2026 · After close−24.7%
Q1 2026Feb 13, 2026−6.4%
Q4 2025Dec 23, 2025 · After close−23.0%
Q3 2025Aug 12, 2025 · After close−1.5%
Q2 2025May 14, 2025 · After close−11.7%
Q1 2025Feb 12, 2025 · Before open−0.4%
Q4 2024Dec 27, 2024 · After close+6.3%
Q3 2024Aug 12, 2024 · After close−11.7%
Q2 2024May 14, 2024 · After close−9.2%
All 20 quarters
QuarterResultsShare move
Q1 2024Feb 14, 2024 · After close+9.1%
Q4 2023Dec 29, 2023 · After close+6.9%
Q3 2023Aug 14, 2023 · After close−6.7%
Q2 2023May 12, 2023 · After close−9.2%
Q1 2023Feb 10, 2023 · After close−9.3%
Q4 2022Dec 22, 2022 · After close−18.0%
Q3 2022Aug 11, 2022 · After close−1.7%
Q2 2022May 12, 2022 · After close−0.3%
Q1 2022Feb 10, 2022 · After close0.0%
Q4 2021Dec 15, 2021 · After close−5.9%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (December 2025)Investor deck28 slidesDec 1, 2025
Investor Presentation (October 2025)Investor deck26 slidesOct 23, 2025
Investor Presentation (March 2025)Investor deck24 slidesMarch 2025
Investor Presentation (January 2025)Investor deck27 slidesJanuary 2025
SPAC Merger (October 2023)SPAC merger33 slidesOct 24, 2023
Investor Presentation (September 2023)Investor deck28 slidesSeptember 2023
Investor Presentation (June 2023)Investor deck29 slidesJune 2023
Investor Presentation (February 2023)Investor deck30 slidesFebruary 2023
64th American Society of Hematology (ASH) Annual Meeting 2022Conference19 slidesDec 11, 2022
Investor Presentation (December 2022)Investor deck30 slidesDecember 2022
All 27 decks
DeckKindSlidesDate
Investor Presentation (April 2022)Investor deck29 slidesApril 2022
Investor Presentation (January 2022)Investor deck28 slidesJanuary 2022
Investor Presentation (September 2021)Investor deck38 slidesSeptember 2021
Investor Presentation (July 2021)Investor deck29 slidesJul 7, 2021
Benzinga Global Small Cap Conference 2021Conference37 slidesMay 13, 2021
Investor Presentation (February 2021)Investor deck53 slidesFeb 16, 2021
Investor Presentation (January 2021)Investor deck42 slidesJan 11, 2021
Investor Presentation (August 2020)Investor deck36 slidesAug 26, 2020
Investor Presentation (April 2020)Investor deck39 slidesApr 29, 2020
Investor Presentation (January 2020)Investor deck37 slidesJan 22, 2020
Investor Presentation (September 2019)Investor deck41 slidesSep 19, 2019
Investor Presentation (February 2019)Investor deck50 slidesFeb 19, 2019
Investor Presentation (December 2018)Investor deck40 slidesDec 12, 2018
Investor Presentation (August 2018)Investor deck38 slidesAug 1, 2018
Investor Presentation (December 2017)Investor deck41 slidesDec 1, 2017
Investor Presentation (November 2017)Investor deck47 slidesNov 7, 2017
Investor Presentation (July 2017)Investor deck27 slidesJul 13, 2017

Open Decks

Financings

RaiseDate
Registered direct offering of shares of common stock (or pre-funded warrants)
Closed: US$5M raised · US$0.985 a share · Warrants at US$0.86 for 60 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Commercial launch of LYMPHIR including milestone and regulatory payments, development of product candidates, and general corporate purposes
Apr 27, 2026
Registered direct offering of shares of common stock (or pre-funded warrants in lieu thereof) and accompanying common warrants
Closed: US$6M raised · US$1.51 a share · Warrants at US$1.4 for 60 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Support the commercial launch of LYMPHIR, including milestone and regulatory payments, development of product candidates, and general corporate purposes
Oct 21, 2025
Registered direct offering of shares of common stock (or pre-funded warrants in lieu thereof) and accompanying short-term warrants
Closed: US$6M raised · US$1.22 a share · Warrants at US$1 for 24 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Support the commercial launch of LYMPHIR, including milestone, regulatory and other payments, and general corporate purposes
Jun 12, 2025
Registered direct offering of shares of common stock (or pre-funded warrants in lieu thereof)
Announced: about US$2M · US$1.15 a share · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Support the commercial launch of LYMPHIR and general corporate purposes
Apr 1, 2025
Registered direct offering of shares of common stock and accompanying warrants
Announced: about US$3M · US$4.035 a share · Warrants at US$3.91 for 60 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: General corporate purposes, including pre-clinical and clinical development of product candidates, working capital and capital expenditures
Jan 8, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue90.0K90.0K90.0K90.0K75.0K50.0K
Cost of revenue75.0K50.0K45.0K
Gross profit00
Research and development9.16M11.9M14.8M17.7M12.2M8.81M8.60M6.56M2.94M2.93M
Operating income-38.5M-42.0M-36.7M-33.3M-23.5M-17.7M-15.6M-13.8M-9.99M-7.45M
Depreciation and amortization1.43K2.67K2.92K1.49K8448931.75K2.63K1.34K
EBITDA-42.0M-36.7M-33.3M-23.5M-17.7M-15.6M-13.8M-9.98M-7.45M
Interest expense267.8K10.8K15.7K16.4K15.8K850.8K8.99K
Income before tax-38.7M-38.8M-32.0M-33.1M-23.1M-17.5M-15.6M12.5M10.4M-8.30M
Income tax1.06M576.0K576.0K576.0K1.23K741
Net income-37.4M-40.2M-32.5M-33.6M-23.1M-17.5M-15.6M-12.5M-10.4M-8.30M
Earnings per share, basic-3.38-5.97-5.57-0.23-0.23-0.45-0.77-1.17-1.89-2.29
Earnings per share, diluted-3.38-5.97-5.57-0.23-0.23-0.45-0.77-1.17-1.89-2.29

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents4.25M3.25M26.5M41.7M70.1M13.9M7.89M9.18M3.20M294.4K
Inventory22.3M8.27M
Current assets27.9M14.2M34.4M44.6M72.8M14.0M7.94M10.1M3.42M892.8K
Property, plant and equipment1.43K4.10K7.02K1.58K5901.48K3.24K3.74K
Goodwill9.35M9.35M9.35M9.35M9.35M9.35M9.35M1.59M1.59M1.59M
Total assets130.9M116.7M103.6M114.0M142.4M43.8M36.7M31.1M24.4M22.0M
Accounts payable13.7M4.93M2.93M1.17M1.28M1.86M2.71M1.57M602.4K909.2K
Current liabilities44.9M35.8M5.78M4.53M3.98M4.10M4.61M3.18M2.47M5.18M
Total liabilities53.4M42.5M12.2M10.6M9.65M10.1M9.59M
Shareholders' equity67.6M70.1M90.8M102.8M132.2M33.7M27.2M30.6M21.9M16.8M
Shares outstanding18.1M7.25M6.35M146.2M146.0M55.6M28.9M16.2M8.35M4.88M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-26.6M-28.2M-29.1M-28.4M-24.3M-16.9M-12.4M-11.3M-7.97M-5.90M
Capital spending-6.94K-1.83K-2.13K
Free cash flow-24.3M-16.9M-7.97M
Cash from investing-5.75M-5.00M-40.0M-1.83K-2.13K255.7K
Cash from financing33.3M9.97M13.8M120.5M22.9M11.1M17.3M10.9M5.26M
Change in cash1.00M-23.2M-15.2M-28.4M56.2M5.97M-1.29M5.98M2.91M-381.8K

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 4, 2026Current reportSEC
8-K · Current reportOct 26, 2026ResultsSEC
8-K · Current reportAug 21, 2026Current reportSEC
10-Q · Quarterly reportAug 14, 2026Quarterly reportSEC
8-K · Current reportAug 14, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
UPLOAD · Letter from the SECAug 10, 2026Other filingsSEC
8-K · Current reportAug 5, 2026Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedJun 4, 2026Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveJun 3, 2026Other filingsSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportJun 1, 2026Current reportSEC
CORRESP · Letter to the SECMay 29, 2026Other filingsSEC
S-3 · Registration statementMay 22, 2026Offer documentSEC
8-K · Current reportMay 15, 2026ResultsSEC
10-Q · Quarterly reportMay 15, 2026Quarterly reportSEC
8-K · Current reportMay 8, 2026Material contractSEC
8-K · Current reportApr 29, 2026FinancingSEC
8-K · Current reportApr 24, 2026Material contractSEC
424B5 · ProspectusApr 24, 2026Offer documentSEC
8-K · Current reportApr 6, 2026Meeting outcomeSEC
8-K · Current reportMar 31, 2026Current reportSEC
8-K · Current reportMar 10, 2026Current reportSEC
8-K · Current reportMar 4, 2026Current reportSEC
ARS · Annual report to shareholdersFeb 24, 2026Annual reportSEC
DEFA14A · Additional proxy materialFeb 24, 2026Meeting noticeSEC
DEF 14A · Proxy statementFeb 24, 2026Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
8-K · Current reportFeb 13, 2026ResultsSEC
10-Q · Quarterly reportFeb 13, 2026Quarterly reportSEC
10-K/A · Annual report, amendedJan 28, 2026Annual reportSEC
8-K · Current reportDec 23, 2025ResultsSEC
10-K · Annual reportDec 23, 2025Annual reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedDec 17, 2025Big-stake noticeSEC
8-K · Current reportDec 1, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeOct 27, 2025Big-stake noticeSEC
8-K · Current reportOct 23, 2025Current reportSEC
8-K · Current reportOct 21, 2025Material contractSEC
424B5 · ProspectusOct 21, 2025Offer documentSEC
4 · Change in ownershipSep 23, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedSep 12, 2025Big-stake noticeSEC
4 · Change in ownershipAug 12, 2025Insider tradeSEC
8-K · Current reportAug 12, 2025ResultsSEC
10-Q · Quarterly reportAug 12, 2025Quarterly reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedJul 25, 2025Big-stake noticeSEC
8-K · Current reportJul 8, 2025Current reportSEC
8-K · Current reportJun 12, 2025Material contractSEC
424B5 · ProspectusJun 11, 2025Offer documentSEC
8-K · Current reportJun 9, 2025Meeting outcomeSEC
8-K · Current reportJun 3, 2025Material contractSEC
8-K · Current reportMay 30, 2025Current reportSEC
10-Q · Quarterly reportMay 14, 2025Quarterly reportSEC
8-K · Current reportMay 14, 2025ResultsSEC
DEFA14A · Additional proxy materialApr 28, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 28, 2025Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 18, 2025Meeting noticeSEC
8-K · Current reportApr 18, 2025Material contractSEC
8-K · Current reportApr 3, 2025Material contractSEC
8-K · Current reportApr 2, 2025Material contractSEC
424B5 · ProspectusApr 2, 2025Offer documentSEC
8-K · Current reportMar 10, 2025Meeting outcomeSEC
8-K · Current reportFeb 14, 2025Current reportSEC
10-Q · Quarterly reportFeb 14, 2025Quarterly reportSEC
8-K · Current reportFeb 6, 2025Current reportSEC
10-K/A · Annual report, amendedJan 27, 2025Annual reportSEC
ARS · Annual report to shareholdersJan 27, 2025Annual reportSEC
DEFA14A · Additional proxy materialJan 27, 2025Meeting noticeSEC
DEF 14A · Proxy statementJan 27, 2025Meeting noticeSEC
PRE 14A · Preliminary proxy statementJan 16, 2025Meeting noticeSEC
8-K · Current reportJan 8, 2025Material contractSEC
424B5 · ProspectusJan 8, 2025Offer documentSEC
8-K · Current reportJan 7, 2025Current reportSEC
8-K · Current reportDec 27, 2024ResultsSEC
10-K · Annual reportDec 27, 2024Annual reportSEC
8-K · Current reportDec 20, 2024Current reportSEC
SC 13D/A · Big-stake notice, amendedNov 27, 2024Big-stake noticeSEC
8-K · Current reportNov 26, 2024Current reportSEC
8-K · Current reportNov 25, 2024Current reportSEC
8-K · Current reportNov 18, 2024Material contractSEC
424B5 · ProspectusNov 18, 2024Offer documentSEC
8-K · Current reportNov 13, 2024Current reportSEC
4 · Change in ownershipNov 12, 2024Insider tradeSEC
4 · Change in ownershipNov 12, 2024Insider tradeSEC
4 · Change in ownershipNov 12, 2024Insider tradeSEC
4 · Change in ownershipNov 12, 2024Insider tradeSEC
4 · Change in ownershipNov 12, 2024Insider tradeSEC
4 · Change in ownershipNov 12, 2024Insider tradeSEC
4 · Change in ownershipNov 12, 2024Insider tradeSEC
4 · Change in ownershipNov 12, 2024Insider tradeSEC
4 · Change in ownershipNov 12, 2024Insider tradeSEC
8-K · Current reportNov 12, 2024Current reportSEC
4 · Change in ownershipSep 27, 2024Insider tradeSEC
4 · Change in ownershipSep 27, 2024Insider tradeSEC
8-K · Current reportSep 27, 2024Material contractSEC
8-K · Current reportSep 13, 2024Material contractSEC
8-K · Current reportSep 11, 2024Current reportSEC
8-K · Current reportSep 5, 2024Current reportSEC
4 · Change in ownershipAug 30, 2024Insider tradeSEC
4 · Change in ownershipAug 30, 2024Insider tradeSEC
8-K · Current reportAug 16, 2024Material contractSEC
SC 13D · Big-stake noticeAug 16, 2024Big-stake noticeSEC
4 · Change in ownershipAug 14, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 14, 2024Insider tradeSEC
8-K · Current reportAug 12, 2024ResultsSEC
424B5 · ProspectusAug 12, 2024Offer documentSEC
10-Q · Quarterly reportAug 12, 2024Quarterly reportSEC
8-K · Current reportAug 8, 2024Current reportSEC
8-K · Current reportMay 21, 2024Current reportSEC
8-K · Current reportMay 14, 2024ResultsSEC
10-Q · Quarterly reportMay 14, 2024Quarterly reportSEC
SC 13G/A · Big-stake notice, amendedMay 8, 2024Big-stake noticeSEC
8-K · Current reportApr 30, 2024Material contractSEC
424B5 · ProspectusApr 26, 2024Offer documentSEC
8-K · Current reportApr 5, 2024Current reportSEC
4 · Change in ownershipApr 5, 2024Insider tradeSEC
4 · Change in ownershipApr 5, 2024Insider tradeSEC
4 · Change in ownershipMar 18, 2024Insider tradeSEC
8-K · Current reportMar 18, 2024Current reportSEC
3 · Initial statement of ownershipMar 18, 2024Insider tradeSEC
8-K · Current reportMar 13, 2024Meeting outcomeSEC
EFFECT · Notice that a registration is effectiveMar 4, 2024Other filingsSEC
CORRESP · Letter to the SECFeb 29, 2024Other filingsSEC
UPLOAD · Letter from the SECFeb 29, 2024Other filingsSEC
S-3 · Registration statementFeb 23, 2024Offer documentSEC
S-8 · Registration statement for employee plansFeb 23, 2024Offer documentSEC
8-K · Current reportFeb 15, 2024ResultsSEC
10-Q · Quarterly reportFeb 14, 2024Quarterly reportSEC
8-K · Current reportFeb 14, 2024Current reportSEC
SC 13G · Big-stake noticeJan 31, 2024Big-stake noticeSEC
ARS · Annual report to shareholdersJan 26, 2024Annual reportSEC
DEFA14A · Additional proxy materialJan 26, 2024Meeting noticeSEC
DEF 14A · Proxy statementJan 26, 2024Meeting noticeSEC
8-K · Current reportJan 23, 2024Current reportSEC
8-K · Current reportJan 5, 2024Current reportSEC
8-K · Current reportJan 2, 2024ResultsSEC
10-K · Annual reportDec 29, 2023Annual reportSEC
425Oct 24, 2023Other filingsSEC
8-K · Current reportOct 24, 2023Material contractSEC
4 · Change in ownershipOct 12, 2023Insider tradeSEC
4 · Change in ownershipOct 12, 2023Insider tradeSEC
4 · Change in ownershipOct 12, 2023Insider tradeSEC
4 · Change in ownershipOct 12, 2023Insider tradeSEC
4 · Change in ownershipOct 12, 2023Insider tradeSEC
4 · Change in ownershipOct 12, 2023Insider tradeSEC
4 · Change in ownershipOct 12, 2023Insider tradeSEC
4 · Change in ownershipOct 12, 2023Insider tradeSEC
8-K · Current reportSep 25, 2023Current reportSEC
8-K · Current reportSep 15, 2023Current reportSEC
8-K · Current reportSep 11, 2023Current reportSEC
8-K · Current reportSep 8, 2023Current reportSEC
8-K · Current reportAug 15, 2023ResultsSEC
10-Q · Quarterly reportAug 14, 2023Quarterly reportSEC
8-K · Current reportAug 10, 2023Current reportSEC
8-K · Current reportJul 31, 2023Current reportSEC
8-K · Current reportJun 29, 2023Current reportSEC
8-K · Current reportJun 20, 2023Current reportSEC
8-K · Current reportMay 12, 2023ResultsSEC
10-Q · Quarterly reportMay 12, 2023Quarterly reportSEC
8-K · Current reportMay 8, 2023Material contractSEC
424B5 · ProspectusMay 5, 2023Offer documentSEC
8-K · Current reportApr 24, 2023Current reportSEC
8-K · Current reportApr 3, 2023Current reportSEC
S-8 · Registration statement for employee plansFeb 10, 2023Offer documentSEC
8-K · Current reportFeb 10, 2023ResultsSEC
10-Q · Quarterly reportFeb 10, 2023Quarterly reportSEC
4 · Change in ownershipFeb 9, 2023Insider tradeSEC
3 · Initial statement of ownershipFeb 9, 2023Insider tradeSEC
8-K · Current reportFeb 7, 2023Meeting outcomeSEC
8-K · Current reportDec 22, 2022ResultsSEC
DEFA14A · Additional proxy materialDec 22, 2022Meeting noticeSEC
DEF 14A · Proxy statementDec 22, 2022Meeting noticeSEC
10-K · Annual reportDec 22, 2022Annual reportSEC
8-K · Current reportDec 1, 2022Current reportSEC
8-K · Current reportNov 21, 2022Current reportSEC
4/A · Change in ownership, amendedNov 15, 2022Insider tradeSEC
4 · Change in ownershipOct 6, 2022Insider tradeSEC
4 · Change in ownershipOct 6, 2022Insider tradeSEC
4 · Change in ownershipOct 6, 2022Insider tradeSEC
4 · Change in ownershipOct 6, 2022Insider tradeSEC
4 · Change in ownershipOct 6, 2022Insider tradeSEC
4 · Change in ownershipOct 6, 2022Insider tradeSEC
4 · Change in ownershipOct 6, 2022Insider tradeSEC
4 · Change in ownershipOct 6, 2022Insider tradeSEC
4 · Change in ownershipOct 6, 2022Insider tradeSEC
8-K · Current reportSep 28, 2022Current reportSEC
8-K · Current reportSep 22, 2022Current reportSEC
8-K · Current reportAug 11, 2022ResultsSEC
10-Q · Quarterly reportAug 11, 2022Quarterly reportSEC
25-NSEAug 8, 2022Other filingsSEC
8-K · Current reportJul 12, 2022Current reportSEC
SC 13G · Big-stake noticeJul 8, 2022Big-stake noticeSEC
8-K · Current reportMay 25, 2022Current reportSEC
8-K · Current reportMay 12, 2022ResultsSEC
10-Q · Quarterly reportMay 12, 2022Quarterly reportSEC
8-K · Current reportMay 6, 2022Current reportSEC
8-K · Current reportApr 26, 2022Current reportSEC
8-K · Current reportApr 13, 2022Management or board changeSEC
8-K · Current reportApr 6, 2022Current reportSEC
SC 13D/A · Big-stake notice, amendedFeb 18, 2022Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedFeb 18, 2022Big-stake noticeSEC
8-K · Current reportFeb 15, 2022Current reportSEC

This page holds 200 of 638 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Citius Pharmaceuticals, Inc.’s releases · as of Aug 13, 2026

Common shares
27,452,570
Fully diluted
27,452,570

Fully diluted

LineSharesAs of
Common shares27,452,570Aug 13, 2026

Warrants and options

Lot
Warrants · US$0.86 · expire about Apr 2031
Warrants · US$1.40 · expire about Oct 2030
Warrants · US$1.00 · expire about Jun 2027

Share count over time

CountShares
Aug 13, 202627,452,570

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Vanguard430K1.6%US$228KSep 30, 2026
Geode Capital255K0.93%US$135KSep 30, 2026
Miller Financial Services LLC154K0.56%US$81,774Sep 30, 2026
BlackRock69,8500.25%US$37,090Sep 30, 2026
Northern Trust62,7420.23%US$33,316Sep 30, 2026
Asset Advisory Group, Inc.59,0110.21%US$31,335Sep 30, 2026
StoneX Group Inc.36,4140.13%US$20,047Sep 30, 2026
UBS36,2870.13%US$19,268Sep 30, 2026
Berthel, Fisher & Company Financial Services, Inc.29,3500.11%US$15,585Sep 30, 2026
Two Sigma23,3310.08%US$12,389Sep 30, 2026
All 33 holders
HolderSharesOf the companyValueAs of
State Street23,2710.08%US$12,357Sep 30, 2026
Hrt Financial LP18,2750.07%US$9,000Sep 30, 2026
Susquehanna15,9360.06%US$8,462Sep 30, 2026
SBI Securities Co., Ltd.13,5190.05%US$7,179Sep 30, 2026
Quent Capital, LLC4,2320.02%US$2,247Sep 30, 2026
IFP Advisors, Inc4,1830.02%US$2,221Sep 30, 2026
Osaic Holdings, Inc.2,391<0.01%US$1,265Sep 30, 2026
Tower Research Capital LLC (TRC)2,032<0.01%US$1,079Sep 30, 2026
RBC1,500<0.01%US$1,000Sep 30, 2026
Group One Trading LLC1,070<0.01%US$568Sep 30, 2026
Wells Fargo1,000<0.01%US$531Sep 30, 2026
Chelsea Counsel Co1,000<0.01%US$531Sep 30, 2026
Citigroup Inc652<0.01%US$346Sep 30, 2026
Simplex Trading, LLC584<0.01%US$310Sep 30, 2026
Luminist Capital LLC435<0.01%US$231Sep 30, 2026
Princeton Global Asset Management LLC160<0.01%US$85Sep 30, 2026
JPMorgan120<0.01%US$67Sep 30, 2026
BNP Paribas107<0.01%US$57Sep 30, 2026
Arax Advisory Partners84<0.01%US$45Sep 30, 2026
Federation des caisses Desjardins du Quebec80<0.01%US$42Sep 30, 2026
Root Financial Partners, LLC50<0.01%US$27Sep 30, 2026
Bogart Wealth, LLC4<0.01%US$2Sep 30, 2026
Morgan Stanley4<0.01%US$2Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Extended Market Index Fund168K0.61%US$101KJun 30, 2026
Fidelity Extended Market Index Fund148K0.54%US$96,987May 31, 2026
Fidelity Series Total Market Index Fund26,3590.10%US$17,263May 31, 2026
Fidelity Total Market Index Fund11,6550.04%US$7,633May 31, 2026

Big stakes

StakeStakeSharesDateFiling
CVI Investments, Inc.9.90%3.01MJun 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Dennis M. McGrath
Other companies: Citius Oncology, Inc. (Director · Since at least Aug 12, 2024); Lucid Diagnostics Inc. (Chief Financial Officer · Since at least Oct 13, 2021); PAVmed Inc. (President and CFO · Since at least Feb 14, 2018); DarioHealth Corp. (Board Member · Since at least Oct 23, 2017)
Director · Since at least Feb 7, 2023
Leonard Mazur
Other companies: Citius Oncology, Inc. (Chairman · Since at least Aug 12, 2024); Canton Strategic Holdings, Inc. (Director · Jan 11, 2022 – Aug 9, 2024 · Past)
Co-Founder, CEO and Chairman of the Board of Directors · Since at least Mar 30, 2016
Myron Holubiak
Other companies: Citius Oncology, Inc. (Secretary · Since at least Aug 12, 2024); Assembly Biosciences, Inc. (Director · May 30, 2018 – May 20, 2021 · Past)
Co-Founder, Executive Vice Chairman · Since at least Mar 28, 2018
Carol Webb
Other companies: Citius Oncology, Inc. (Director · Since at least Nov 5, 2026)
Director · Since at least Nov 5, 2026
Eugene Holuka
Other companies: Citius Oncology, Inc. (Director · Since at least Aug 12, 2024)
Director · Since at least Oct 6, 2020
Howard Safir
Other companies: Verint Systems Inc (Director · Apr 20, 2018 – Apr 20, 2021 · Past)
Director · Sep 4, 2018 – Oct 4, 2022 · Past
Jaime Bartushak
Other companies: Citius Oncology, Inc. (Chief Financial Officer · Since at least Aug 12, 2024)
Chief Financial Officer & Chief Business Officer · Since at least Oct 6, 2020
Robert Smith
Other companies: Citius Oncology, Inc. (Director · Since at least Aug 12, 2024)
Director · Since at least Mar 12, 2024
Suren Dutia
Other companies: Citius Oncology, Inc. (Director · Since at least Nov 5, 2026)
Director · Since at least Nov 5, 2026
Alan LaderSVP, Head of Clinical Operations and Quality Assurance · Since at least Nov 5, 2026
All 19 people
PersonSeat
Catherine KesslerEVP, Regulatory Affairs · Since at least Nov 5, 2026
Gary F. TalaricoEVP, Operations · Since at least Nov 5, 2026
Jay WadekarSVP, Business Strategy · Since at least Nov 5, 2026
Kelly CreightonEVP, Chemistry, Manufacturing and Controls · Since at least Nov 5, 2026
Kevin CareyVP, Program & Alliance Management · Since at least Nov 4, 2026
Michael McGuireVP, Commercial · Since at least Jul 21, 2026
Myron S. CzuczmanChief Medical Officer and EVP · Since at least Jun 1, 2026
Nikolas BurlewEVP, Quality Assurance · Since at least Nov 5, 2026
William KaneDirector · Oct 6, 2020 – Oct 4, 2022 · Past

Open People

Log in to ask 6ix AI your own questions about Citius Pharmaceuticals, Inc.